Articles tagged with: Maintenance Therapy

News»

[ by and | Apr 19, 2013 2:29 pm | 11 Comments ]
Update On Benefits And Risks Of Revlimid Maintenance Therapy (IMW 2013)

Further findings from two clinical studies of Revlimid maintenance thera­py were presented at the 14th International Myeloma Workshop (IMW) in Kyoto, Japan, earlier this month.

Both studies involved newly diagnosed multiple myeloma patients who received maintenance therapy with Revlimid (lenalidomide).

Results from both studies, which were published in the New England Journal of Medicine last May, indicate that Revlimid maintenance therapy significantly increases progression-free survival compared to a placebo (see related Beacon news). One of the studies also found that Revlimid maintenance therapy improved overall survival of patients. …

Read the full story »

News»

[ by | Mar 22, 2013 2:52 pm | 4 Comments ]
The Top Myeloma Research Of 2012

Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many im­por­tant devel­op­ments that took place.

There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Adminis­tra­tion (FDA).  Prior to 2012, the FDA had not approved a novel anti-myeloma therapy in over six years.

Yet 2012 was meaningful to the myeloma community for reasons beyond the activity at …

Read the full story »

Opinion»

[ by | Feb 21, 2013 12:44 pm | 29 Comments ]
ME vs. MM: Life After Dex

Perhaps the title of this column more appropriately should be "Life After CRD," since I've now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lena­lido­mide), and dexa­metha­sone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.

However, since dexa­metha­sone seemed to be the predominate source of my side effects, and be­cause I liked the play on words, I went with the title as shown.

So, I've completed the clinical trial, I've reached stringent complete response, and I've won …

Read the full story »

Opinion»

[ by | Dec 4, 2012 1:25 pm | 24 Comments ]
Sean’s Burgundy Thread: Wednesdays With Murray

While I am not so much a creature of habit, my Wednesday afternoon activities over the last three years have been pretty much chiseled in stone.

At around noon on a typical Wednesday, I drop everything that I’m doing, jump into my car, drive across the Kimberling City Bridge that sits perched 30 feet above beautiful Table Rock Lake, and then wind my way through the rolling Ozark hills and picturesque hollows toward the nationally known tourist and entertainment small city of Branson, Missouri.

Upon arrival at my destination, I …

Read the full story »

News»

[ by | Aug 29, 2012 3:43 pm | Comments Off ]
Velcade-Thalidomide And Velcade-Prednisone May Be Effective As Maintenance Therapy For Elderly Myeloma Patients

Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus pred­nisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.

In addition, elderly myeloma patients who receive Velcade plus thalido­mide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus pred­nisone as maintenance therapy.

“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the dif­ferences didn't …

Read the full story »